弥漫大B细胞淋巴瘤靶向药物治疗进展：第55届美国血液学会年会报道

Progress of targeted therapy in diffuse large B-cell lymphoma： reports in the 55th ASH annual meeting

随着对弥漫大B细胞淋巴瘤（DLBCL）异质性和分子机制的研究加深,诞生了许多新型的分子靶向药物,并且早期研究显示临床获益.DLBCL的治疗靶点主要包括B淋巴细胞表面抗原、B细胞内信号转导通路和细胞微环境.第55届美国血液学会（ASH）年会上报道了多项关于靶向治疗DLBCL的最新临床试验,结果令人鼓舞.现结合第55届ASH年会上的最新报告,对DLBCL分子靶向药物治疗的现状及重要进展进行阐述.

With the further study on heterogeneity and molecular mechanism of diffuse large B-cell lymphoma （DLBCL）,many novel targeted drugs have been developed,which also showed clinical benefit in early-stage studies.Therapeutic targets for DLBCL mainly include the surface antigens of B lymphocyte,B cell receptor signaling and the cellular microenvironment.Several new clinical trials about targeted therapy for DLBCL had been reported in the 55th ASH annual meeting,and the results were encouraging.The advances in this field will be summarized in this paper based on the new reports in the 55th ASH annual meeting.